B
Bret A. Lashner
Researcher at University of Chicago
Publications - 110
Citations - 6779
Bret A. Lashner is an academic researcher from University of Chicago. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 38, co-authored 110 publications receiving 6530 citations. Previous affiliations of Bret A. Lashner include Cleveland Clinic Lerner Research Institute & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
Paul Rutgeerts,Robert H. Diamond,Mohan Bala,Allan Olson,Gary R. Lichtenstein,Weihang Bao,Kamlesh Patel,Douglas C. Wolf,Michael Safdi,Jean-Frederic Colombel,Bret A. Lashner,Stephen B. Hanauer +11 more
TL;DR: Scheduled infliximab maintenance therapy resulted in more improvement in mucosal ulceration and in higher rates of mucosal healing, and there was a numerical trend for patients with better mucosal Healing to have a lower rate of Crohn's disease-related hospitalizations.
Journal ArticleDOI
A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis
Bo Shen,Jean Paul Achkar,Bret A. Lashner,Adrian H. Ormsby,Feza H. Remzi,Aaron Brzezinski,Charles L. Bevins,Marlene L. Bambrick,Douglas L. Seidner,Victor W. Fazio +9 more
TL;DR: Ciprofloxacin produces a greater reduction in the PDAI and a greater improvement in symptom and endoscopy scores, and is better tolerated than metronidazole and should be considered as one of the first-line therapies for acute pouchitis.
Journal ArticleDOI
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis: A case-control study
TL;DR: Pending a larger case-control study, folate supplementation during sulfasalazine administration is recommended to possibly prevent the complication of dysplasia or cancer in ulcerative colitis.
Journal ArticleDOI
Cytomegalovirus colitis complicating inflammatory bowel disease.
Ahmed Kandiel,Bret A. Lashner +1 more
TL;DR: When patients with inflammatory bowel disease (IBD) are admitted to the hospital with a flare of acute severe colitis, the possibility of a concurrent cytomegalovirus (CMV) infection causing or worsening the colitis is often considered.